Transarterial Chemoembolization Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Rising Hepatocellular Carcinoma Incidence

Liver cancer incidence provides the demand base for the transarterial chemoembolization market. GLOBOCAN recorded 843,045 new liver and intrahepatic bile duct cancer cases in 2024, and the disease ranked third in cancer mortality with 732,489 deaths.^[1] Hepatocellular carcinoma represents 75% to 85% of these cases, linking the burden directly to TACE procedure demand. Chronic HBV and HCV infection remain important precursors, while low treatment coverage leaves many patients at continued risk. Global liver cancer incidence could reach 1.52 million new cases annually by 2050 if current viral hepatitis control trends continue.^[2] MASLD is also widening the future patient pool in North America and Western Europe beyond the historical hepatitis B population.

Shift Toward Minimally Invasive and Locoregional Therapy

Resection and transplantation are curative options for fewer than 20% of patients at diagnosis, leaving many intermediate-stage cases dependent on locoregional treatment. TACE is established in BCLC and AASLD treatment pathways for BCLC-B unresectable hepatocellular carcinoma. This supports the transarterial chemoembolization market because catheter-based care can serve patients who are not eligible for surgery. The movement toward outpatient oncology care also favors procedures that avoid inpatient surgical admissions. The 2026 Medicare Physician Fee Schedule created a net 2% increase for interventional radiology and a 7% increase in non-facility settings.^[3] This reimbursement mechanics support outpatient volume while increasing the difference in access between facility-based and community providers.

Drug-Eluting Bead and Image-Guided Technology Adoption

Drug-eluting bead TACE combines arterial occlusion with controlled local drug release through calibrated microspheres. This approach can reduce peak plasma chemotherapy exposure and systemic toxicity compared with lipiodol-based procedures. A 2024 review found lower rates of grade 3 or higher systemic adverse events with DEB-TACE than with conventional TACE in hepatocellular carcinoma. A randomized phase 4 study also found superior efficacy for idarubicin over epirubicin in the DEB-TACE setting. A multicenter study reported that an MRI and clinical-variable model predicted TACE response with AUC values of 0.91 in training and 0.84 in validation cohorts. The transarterial chemoembolization market is therefore placing more value on imaging compatibility and workflow support, not only bead drug-loading performance.

TACE and Immunotherapy Combination Regimen Adoption

TACE is being used more often alongside systemic immunotherapy in intermediate-stage hepatocellular carcinoma. Tumor ischemia and necrosis after TACE can release neoantigens and activate dendritic-cell activity, which may strengthen the effect of checkpoint inhibitors. A phase 2 study reported improved tumor control with TACE, atezolizumab, and bevacizumab in intermediate-stage disease. The TALENTACE phase 3 trial reported a positive primary endpoint for atezolizumab plus bevacizumab combined with TACE. China approved lenvatinib plus pembrolizumab with TACE for unresectable non-metastatic hepatocellular carcinoma in July 2025. This places greater importance on microcatheter technique and embolic loading, since treatment quality affects the local conditions for combination care.

Procedure-Related Complications and Liver Decompensation

Post-procedure liver dysfunction limits repeat treatment and remains a central restraint on the transarterial chemoembolization market. A retrospective study of 549 patients found liver function impairment in 61.9% of patients after TACE and post-embolization syndrome in 27.0%. The study identified Child-Pugh class, neutrophil count, and baseline ECOG score as independent predictors of hepatic dysfunction. More severe decompensation can include ascites, encephalopathy, coagulopathy, and variceal bleeding. Patients with cirrhosis and limited hepatic reserve are especially exposed to this risk. Different monitoring intervals and escalation thresholds across treatment centers can also create uneven treatment decisions and lower procedure volumes at more cautious institutions.

High Equipment, Procedure, and Training Costs

A TACE program requires angiography equipment, contrast agents, microcatheters, guidewires, and embolic products. These requirements restrict adoption in smaller hospitals and lower-income health systems. Interventional radiologists also need experience in hepatic arterial mapping, selective catheterization, and embolic endpoint assessment. This training is difficult to provide where procedure volumes and structured mentorship are limited. The Society of Interventional Radiology opposed the WISeR model, which began in 6 U.S. states in 2026, because prior authorization and prepayment review could restrict access to selected image-guided services. Administrative review can be particularly difficult when the clinical decision requires procedural judgment that is not fully captured in automated evaluation.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Transarterial Chemoembolization Market Segment Analysis

Conventional TACE held 53.32% of the transarterial chemoembolization market share in 2026. Its position rests on extensive clinical experience, practitioner familiarity, and compatibility with cisplatin, doxorubicin, and epirubicin regimens. Conventional TACE is projected to grow at a 6.22% CAGR from 2027 to 2032 because emerging liver cancer programs can adopt lipiodol-based methods before investing in DEB-TACE platforms. Guerbet Lipiodol supply chains and flexible drug selection support use in European and Asian health systems with generic chemotherapy formularies.

DEB-TACE is gaining use in centers with dedicated microsphere platforms, including Boston Scientific’s LC Bead LUMI and Merit Medical’s HepaSphere. Conventional TACE was used in 59.3% of patients in the combination arm, while DEB-TACE was used in 40.7%. The result indicates that TACE’s immune-priming role is not limited to one procedure type. DEB-TACE offers local drug-delivery and imaging-related benefits that influence purchasing decisions.

Chemotherapeutic agents accounted for 43.35% of the transarterial chemoembolization market share in 2026. The category includes doxorubicin, cisplatin, mitomycin C, and epirubicin delivered in lipiodol emulsions or through intra-arterial infusion. Its scale reflects the continued global importance of conventional TACE and generic chemotherapy availability in emerging markets. Radiotherapeutic and adjacent intra-arterial agents serve patients whose liver reserve or contraindications limit conventional drug delivery.

Drug-eluting particles are expected to be the fastest-growing product type, with a 6.71% CAGR forecasted through 2032. Boston Scientific, Merit Medical, and Terumo hold important positions, while ABK Biomedical completed ROUTE90 phase 3 pivotal-study enrollment for Eye90 in February 2026. ABK Biomedical and COR Development announced commercial manufacturing in Ashland, Missouri, in April 2026, showing the movement of imaging-enabled embolics toward commercial supply.

Hepatocellular carcinoma accounted for 44.53% of the transarterial chemoembolization market in 2026. BCLC guidance supports TACE for Stage B unresectable disease, making HCC the primary source of procedure volume. The 843,045 liver and intrahepatic bile duct cancer cases recorded in 2024 support continued HCC-directed care, and HCC makes up 75% to 85% of this disease group. Centers are assessing procedure selection and embolization quality more closely when planning checkpoint inhibitor co-administration.

Metastatic liver cancer is anticipated to grow at a 7.11% CAGR through 2032. Rising liver metastases from colorectal and breast cancer in aging Western populations are expanding use beyond HCC. A multicenter cohort study found better disease control with DEB-TACE, systemic chemotherapy, and immune checkpoint inhibitors than with systemic therapy alone in unresectable intrahepatic cholangiocarcinoma. Metastatic neuroendocrine tumors and hepatoblastoma provide smaller but stable procedure volumes across hypervascular liver tumor types.

Hospitals held 45.13% of the transarterial chemoembolization market share in 2026. They can provide biplane angiography, post-procedure liver monitoring, and multidisciplinary tumor board support. Large academic medical centers in the United States, Germany, and Japan combine high procedure volumes with clinical research activity that shapes treatment protocols. Hospital capacity remains important where patients need close assessment of liver function after treatment.

Cancer research centers are projected to grow at a 5.77% CAGR through 2032. They are central to phase 2 and phase 3 protocols combining TACE with PD-1 or PD-L1 inhibitors, tyrosine kinase inhibitors, and anti-VEGF agents. Ambulatory surgical centers are emerging for appropriate outpatient procedures because the 2026 Medicare schedule supports non-facility interventional radiology care. Specialized hepatology clinics and imaging centers with catheterization capability serve residual volume in high-income settings.

Geography Analysis

North America

North America held 47.26% of the transarterial chemoembolization market share in 2026. Medicare and commercial reimbursement, dense interventional radiology networks, and specialized liver tumor boards support this position. The 2026 Medicare fee schedule increased interventional radiology payment by 2% overall and by 7% in non-facility settings. The United States leads regional procedure volume, Canada adds demand through provincial cancer care networks, and Mexico is growing as tertiary infrastructure expands.

Asia-Pacific

Asia-Pacific is projected to grow at an 8.12% CAGR from 2027 to 2032, the highest regional rate in the transarterial chemoembolization market. The region has the largest absolute HCC burden and is expanding interventional oncology capacity. China’s 2025 combination approval has encouraged investment in more precise TACE delivery. Japan maintains high volumes through universal health coverage and favorable reimbursement, although Y-90 reimbursement has increased radioembolization competition.

Europe, Middle East and Africa

Europe follows North America, with Germany, the United Kingdom, France, Italy, and Spain as core markets. The transarterial chemoembolization market in the Middle East and Africa has varied conditions. Saudi Arabia, the UAE, and Qatar combine high healthcare spending, available interventional infrastructure, and expanding cancer center capacity. South Africa and much of sub-Saharan Africa face equipment and specialist shortages despite unmet need linked to HBV-related disease and aflatoxin B1 exposure. Brazil and Argentina are expanding training and professional registries, while Brazil’s SUS system provides partial reimbursement for locoregional liver cancer procedures.